HOSPITAL UNIVERSITARIO RUBER
Departamento
University of Milan
Milán, ItaliaPublicaciones en colaboración con investigadores/as de University of Milan (63)
2024
-
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
The Lancet
-
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
Breast Cancer Research and Treatment
-
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)
Radiotherapy and Oncology
-
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83
-
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)
ESMO Open, Vol. 9, Núm. 3
-
Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis
Frontiers in Immunology, Vol. 15
-
The evolving value assessment of cancer therapies: Results from a modified Delphi study
Health Policy OPEN, Vol. 6
2023
-
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial
JAMA Network Open, Vol. 6, Núm. 4, pp. E235822
-
Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3)
Pediatric Research
-
DESTINY-Breast03 trial: some questions remain – Authors' reply
The Lancet
-
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659
-
Evaluation of triple negative breast cancer with heterogeneous immune infiltration
Frontiers in Immunology, Vol. 14
-
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
ESMO Open, Vol. 8, Núm. 4
-
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 2, pp. 198-205
-
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 67-80
-
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis
Cancer Treatment Reviews, Vol. 119
-
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials
Breast, Vol. 69, pp. 258-264
-
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
The Lancet, Vol. 401, Núm. 10371, pp. 105-117
-
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
Annals of Oncology
2022
-
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
CA Cancer Journal for Clinicians, Vol. 72, Núm. 2, pp. 165-182